cancer, clinical trials

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

Protesters crash the BIO conference to protest the delayed approval of a breast cancer drug.

The regulatory agency will allow early-stage breast cancer patients to try experimental drugs previously reserved for those with advanced disease.

One cancer researcher says that by focusing solely on stalling cancer growth, clinical trials are failing some potentially life-saving drugs that prevent metastasis.

A new bill aims to increase transparency in cancer clinical trials by requiring researchers to divulge all outcomes.

A vaccine that targets 90 percent of all cancers shows promise in early clinical trials.

A new report outlines ways in which omics-based technologies can be shuttled more safely and effectively from the bench to the clinic.

Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to require the inclusion of pediatric patients in clinical drug trials.  

Vitamin D has a variety of actions in the body. It binds to the vitamin D receptor (VDR), which then binds to the retinoid X receptor (RXR) and activates the expression of numerous genes. 

Prevention trials for vitamins and supplements are notoriously difficult, but some researchers aren’t giving up on finding proof that vitamin D helps ward off disease.

New research shows that low-intensity fields can inhibit cancer cell proliferation.

Dwindling stocks in more than a dozen cancer drugs are delaying clinical trials.

A snapshot of the most highly ranked articles in aging research and related areas, from Faculty of 1000

Cancer patients and families of deceased patients filed a lawsuit against Duke University for clinical trials based on flawed data.

In contrast to yesterday’s news about the success of an HPV vaccine program in Australia, an Indian trial of the vaccine is stoking unfounded fear among the public and exposing some questionable ethical standards.

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.

New compounds are showing promise in targeting subpopulations of cancer stem cells.

Understanding oncogenesis at the molecular level offers the prospect of tailoring treatments much more precisely for patients with advanced cases of this deadliest of skin cancers.